On July 29, 2025, Fulcrum Therapeutics announced positive financial results for Q2 2025 and promising findings from its Phase 1b trial of pociredir for sickle cell disease, showing an 8.6% increase in fetal hemoglobin after 12 weeks of treatment. The results highlight improvements in red blood cell health and a reduction in vaso-occlusive crises among patients, indicating the treatment's potential effectiveness.